H. Lundbeck (BATS-CHIXE:HLUNBC) - Stock Price, News & Analysis

HLUNBC Stock Overview

A biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.

About the company

HLUNBC fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	1/6
Past Performance	3/6
Financial Health	5/6
Dividends	2/6

Rewards

Trading at 54.3% below our estimate of its fair value

Earnings are forecast to grow 8.86% per year

Earnings grew by 1.3% over the past year

Risk Analysis

Shares are highly illiquid

H. Lundbeck A/S Competitors

Hikma Pharmaceuticals

LSE:HIK

UK£4.2b

HUTCHMED (China)

AIM:HCM

UK£2.4b

GSK

LSE:GSK

UK£62.2b

Animalcare Group

AIM:ANCR

UK£141.3m

Price History & Performance

Summary of all time highs, changes and price drops for H. Lundbeck
Historical stock prices
Current Share Price	DKK 34.46
52 Week High	DKK 35.79
52 Week Low	DKK 33.14
Beta	0.16
11 Month Change	0%
3 Month Change	n/a
1 Year Change	7.49%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	4.00%

Recent updates

Shareholder Returns

	HLUNBC	GB Pharmaceuticals	GB Market
7D	0%	-1.9%	-1.0%
1Y	7.5%	9.8%	7.3%

Return vs Industry: HLUNBC underperformed the UK Pharmaceuticals industry which returned 9.8% over the past year.

Return vs Market: HLUNBC matched the UK Market which returned 7.3% over the past year.

Price Volatility

Is HLUNBC's price volatile compared to industry and market?
HLUNBC volatility
HLUNBC Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	7.8%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	11.1%
10% least volatile stocks in GB Market	2.7%

Stable Share Price: HLUNBC has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine HLUNBC's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1915	5,681	Charl van Zyl	www.lundbeck.com

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company’s principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson’s disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis.

H. Lundbeck A/S Fundamentals Summary

How do H. Lundbeck's earnings and revenue compare to its market cap?
HLUNBC fundamental statistics
Market cap	DKK 36.84b
Earnings (TTM)	DKK 2.42b
Revenue (TTM)	DKK 20.16b

16.0x

P/E Ratio

1.9x

P/S Ratio

Is HLUNBC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HLUNBC income statement (TTM)
Revenue	DKK 20.16b
Cost of Revenue	DKK 4.45b
Gross Profit	DKK 15.70b
Other Expenses	DKK 13.29b
Earnings	DKK 2.42b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 21, 2024

Earnings per share (EPS)	2.44
Gross Margin	77.91%
Net Profit Margin	11.99%
Debt/Equity Ratio	16.6%

How did HLUNBC perform over the long term?

See historical performance and comparison

Dividends

1.8%

Current Dividend Yield

29%

Payout Ratio

HLUNBC Stock Overview

Rewards

Risk Analysis

H. Lundbeck A/S Competitors

LSE:HIK

UK£4.2b

AIM:HCM

UK£2.4b

LSE:GSK

UK£62.2b

AIM:ANCR

UK£141.3m

Price History & Performance

Recent News & Updates

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Recent updates

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Less than half of directors are independent

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine)

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole

H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti